Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020

Brown, LC; Salgado, R; Luen, SJ; Savas, P; Loi, S

Author(s): Brown, LC; Salgado, R; Luen, SJ; Savas, P; Loi, S;
Details: Publication Year 2021-01,Volume 27,Issue #1,Page 25-31
Journal Title: Cancer Journal
Publication Type: Review
Abstract: Triple-negative breast cancer (TNBC) continues to represent an unmet need because of its significantly poorer outcomes, including higher relapse rates following early-stage disease and dismal survival times in the advanced setting, when compared with other breast cancer subtypes (Cancer 2012;118:5463-5472). Furthermore, there remains a lack of established systemic treatment options beyond conventional cytotoxic chemotherapy, with the exception of PARP inhibitors in the small subset of patients who harbor a BRCA mutation (N Engl J Med 2018;379:753; Lancet Oncol 2020;21:1269-1282; Ann Oncol 2019;30:558-566) and recently the use of immunotherapy in the first-line metastatic setting in those who are programmed death ligand 1-positive (Lancet Oncol 2020;21(1):44-59; N Engl J Med 2018;379(22):2108-2121). Suitable biomarkers for improving prognostication and directing therapy in both the early and advanced TNBC settings are required in order for improvements in survival outcomes to be continued to be attained. Tumor-infiltrating lymphocytes are gaining increasing relevance as an immunological biomarker in this arena.
Keywords: Biomarkers, Tumor; Humans; Immunotherapy; *Lymphocytes, Tumor-Infiltrating/immunology; Neoplasm Recurrence, Local; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use; *Triple Negative Breast Neoplasms/drug therapy/immunology
Department(s): Laboratory Research; Medical Oncology
PubMed ID: 33475290
Publisher's Version: https://doi.org/10.1097/PPO.0000000000000501
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-06-19 06:51:03

Last Modified: 2025-06-19 06:51:41